Abstract
INTRODUCTION
Corticobasal syndrome (CBS) can result from underlying Alzheimer’s disease (AD) pathologies. Little is known about the utility of blood plasma metrics to predict positron emission tomography (PET) biomarker-confirmed AD in CBS.
METHODS
A cohort of eighteen CBS patients (8 amyloid beta [Aβ]+; 10 Aβ−) and 8 cognitively unimpaired (CU) individuals underwent PET imaging and plasma analysis. Plasma concentrations were compared using a Kruskal–Wallis test. Spearman correlations assessed relationships between plasma concentrations and PET uptake.
RESULTS
CBS Aβ+ group showed a reduced Aβ42/40 ratio, with elevated phosphorylated tau (p-tau)181, glial fibrillary acidic protein (GFAP), and neurofilament light (NfL) concentrations, while CBS Aβ− group only showed elevated NfL concentration compared to CU. Both p-tau181 and GFAP were able to differentiate CBS Aβ− from CBS Aβ+ and showed positive associations with Aβ and tau PET uptake.
DISCUSSION
This study supports use of plasma p-tau181 and GFAP to detect AD in CBS. NfL shows potential as a non-specific disease biomarker of CBS regardless of underlying pathology.
Highlights
Plasma phosphorylated tau (p-tau)181 and glial fibrillary acidic protein (GFAP) concentrations differentiate corticobasal syndrome (CBS) amyloid beta (Aβ)− from CBS Aβ+.
Plasma neurofilament light concentrations are elevated in CBS Aβ− and Aβ+ compared to controls.
Plasma p-tau181 and GFAP concentrations were associated with Aβ and tau positron emission tomography (PET) uptake.
Aβ42/40 ratio showed a negative correlation with Aβ PET uptake.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Neha Atulkumar Singh,
Alla Alnobani,
Jonathan Graff‐Radford,
Mary M. Machulda,
Michelle M. Mielke,
Christopher G. Schwarz,
Matthew L. Senjem,
Clifford R. Jack Jr.,
Val J. Lowe,
Takahisa Kanekiyo,
Keith A. Josephs,
Jennifer L. Whitwell | June 18, 2024